Applications for a new antiviral drug

An antiviral drug is given for the first 5 days after the onset of symptoms.

Starting Monday, March 28, 2022, the COVID-19 antiviral drug nirmatrelvir/ritonavir (PAXLOVID®, PFIZER) will be available to people who need therapy. You can apply from Friday, March 25, writes in.gr. A similar procedure will be followed for the drug molnupiravir (LAGEVRIO).

When will it be released and to whom?

An antiviral drug is given for the first 5 days after the onset of symptoms. Application for the drug is made in the first 3 days after the onset of symptoms and after confirmation of COVID-19 infection by rapid antigen (RAPID) or molecular (PCR) test.

The consent of the patient is not required, but he must have a “non-material prescription” (register and get logged in), because after the approval of the application, the medicine must be prescribed by the attending physician (from the electronic prescription platform, according to the usual procedure).

The drug is prescribed for adults and children over 12 years of age weighing more than 40 kg.

Attention! Do not use during pregnancy and lactation, dialysis patients and patients with severe renal insufficiency.

Due to possible interactions between ritonavir and drugs already taken for other conditions, it is recommended that the treating physician of a patient who is being prescribed PAXLOVID® inform the patient of the contraindications.



Source link